Letter by Taylor et al Regarding Article, “Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspectives, Mechanisms, and Future Directions”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Cole et al1 are to be congratulated on a thoughtful, thorough, and especially timely review of hydralazine and nitrates in heart failure. The timeliness is of particular relevance: 2011 marks the 25th anniversary of the publication of the first Vasodilator in Heart Failure Trial (V-HeFT-I),2 which demonstrated that a vasodilator drug could confer a survival benefit in heart failure. Although the precise mechanism of the benefit of combined hydralazine and nitrate was not known at the time (and still requires elucidation), this was nonetheless a sentinel observation. Twenty-five years later, with the outcomes of the African American Heart Failure Trial (A-HeFT)3 as evidence of survival …